BRPI0514606A - sais de lercanidipina - Google Patents

sais de lercanidipina

Info

Publication number
BRPI0514606A
BRPI0514606A BRPI0514606-2A BRPI0514606A BRPI0514606A BR PI0514606 A BRPI0514606 A BR PI0514606A BR PI0514606 A BRPI0514606 A BR PI0514606A BR PI0514606 A BRPI0514606 A BR PI0514606A
Authority
BR
Brazil
Prior art keywords
acids
lercanidipine
salts
acid
amorphous
Prior art date
Application number
BRPI0514606-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Amadeo Leonardi
Markus Von Raumer
Gianni Motta
Original Assignee
Recordati Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati Ireland Ltd filed Critical Recordati Ireland Ltd
Publication of BRPI0514606A publication Critical patent/BRPI0514606A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
BRPI0514606-2A 2004-08-24 2005-08-22 sais de lercanidipina BRPI0514606A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60414904P 2004-08-24 2004-08-24
PCT/EP2005/009043 WO2006021397A1 (en) 2004-08-24 2005-08-22 Lercanidipine salts

Publications (1)

Publication Number Publication Date
BRPI0514606A true BRPI0514606A (pt) 2008-06-17

Family

ID=35159792

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514606-2A BRPI0514606A (pt) 2004-08-24 2005-08-22 sais de lercanidipina

Country Status (19)

Country Link
US (1) US7683179B2 (enExample)
EP (1) EP1799644B1 (enExample)
JP (1) JP2008510754A (enExample)
KR (1) KR20070045351A (enExample)
CN (1) CN101048379A (enExample)
AR (1) AR050467A1 (enExample)
AU (1) AU2005276619B2 (enExample)
BR (1) BRPI0514606A (enExample)
CA (1) CA2575078A1 (enExample)
EA (1) EA011773B1 (enExample)
ES (1) ES2462921T3 (enExample)
IL (1) IL180905A0 (enExample)
MX (1) MX2007002141A (enExample)
NO (1) NO20071515L (enExample)
NZ (1) NZ553127A (enExample)
PE (1) PE20060629A1 (enExample)
TW (1) TW200613275A (enExample)
WO (1) WO2006021397A1 (enExample)
ZA (1) ZA200702364B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05643B1 (et) * 2001-02-24 2013-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ksantiini derivaadid, nende valmistamine ja kasutamine ravimina
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
AR052918A1 (es) * 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
AR053023A1 (es) * 2005-02-25 2007-04-18 Recordati Ireland Ltd Base libre de lercanidipina, metodos para su preparacion y composiciones farmaceuticas que las contienen
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
RU2008151724A (ru) 2006-06-12 2010-07-20 Новартис АГ (CH) Способ получения солей n-гидрокси-3-[4-[[[2-(2-метил-1н-индол-3-ил)этил]амино]метил]фенил]-2е-2-пропенамида
WO2008040367A1 (en) * 2006-08-01 2008-04-10 Union Quimico-Farmaceutica S.A. Lercanidipine hydrobromide, a process for its preparation, crystalline forms and compositions thereof
US20080175872A1 (en) * 2006-09-28 2008-07-24 Osmotica Corp. Controlled Release Dosage Form Containing Lercanidipine and a Performance-enhancing Acid
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
EP2049465A2 (en) * 2007-03-14 2009-04-22 Teva Pharmaceutical Industries Ltd. Processes for preparing solid states of o-desmethylvenlafaxine succinate
WO2009017813A1 (en) * 2007-08-02 2009-02-05 Teva Pharmaceutical Industries Ltd. O-desmethyl venlafaxine saccharinate
KR101343027B1 (ko) 2007-11-26 2013-12-18 테바 파마슈티컬 인더스트리즈 리미티드 O-데스메틸벤라팍신 푸마레이트의 결정형
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
MX2011001240A (es) * 2008-08-01 2011-08-12 Medicines Co Composiciones farmaceuticas y metodos para producir concentraciones de baja impureza de las mismas.
LT2320739T (lt) * 2008-08-01 2020-01-27 Chiesi Farmaceutici S.P.A. Farmacinės kompozicijos ir jų stabilizavimo būdai
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
BRPI0919288A2 (pt) 2008-09-10 2015-12-15 Boehring Ingelheim Internat Gmbh teriapia de combinação para tratamento de diabetes e condições relacionadas.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EA022310B1 (ru) 2008-12-23 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Солевые формы органического соединения
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
KR101409554B1 (ko) * 2010-03-29 2014-06-19 플리바 흐르바츠카 디.오.오. O-데스메틸벤라팍신 푸마레이트의 결정형
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CA2841552C (en) 2011-07-15 2020-06-23 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
JPWO2023219106A1 (enExample) * 2022-05-10 2023-11-16

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8403866D0 (en) 1984-02-14 1984-03-21 Recordati Chem Pharm Diphenylalkylaminoalkyl esters
US5696139A (en) 1995-05-12 1997-12-09 Recordati S.A., Chemical And Pharmaceutical Company Use of S-enantiomers of 1,4-dihydropyridine derivatives for treating heart failure
IT1275532B (it) * 1995-07-14 1997-08-07 Recordati Chem Pharm Uso di derivati 1,4-diidropiridinici per la prevenzione e la terapia della degenerazione aterosclerotica della parete arteriosa
US5912351A (en) 1995-05-12 1999-06-15 Recordati, S.A. Chemical And Pharmaceutical Company Anhydrous 1,4-Dihydropyridines and salts thereof
IT1301759B1 (it) * 1998-06-19 2000-07-07 Nicox Sa Sali nitrati di farmaci antiipertensivi
US6852737B2 (en) 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
US20030069285A1 (en) 2001-08-06 2003-04-10 Recordati Ireland Limited Novel solvate and crystalline forms of lercanidipine hydrochloride
US6699892B2 (en) * 2002-06-04 2004-03-02 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salt of amlodipine and method of preparing the same
WO2004035051A1 (en) * 2002-10-16 2004-04-29 Recordati Ireland Limited Lisinopril/lercanidipine combination therapy
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations

Also Published As

Publication number Publication date
EP1799644A1 (en) 2007-06-27
TW200613275A (en) 2006-05-01
WO2006021397A8 (en) 2006-04-27
US20060047125A1 (en) 2006-03-02
WO2006021397A1 (en) 2006-03-02
NZ553127A (en) 2009-07-31
ES2462921T3 (es) 2014-05-26
CN101048379A (zh) 2007-10-03
EP1799644B1 (en) 2014-02-12
JP2008510754A (ja) 2008-04-10
AU2005276619A1 (en) 2006-03-02
CA2575078A1 (en) 2006-03-02
US7683179B2 (en) 2010-03-23
NO20071515L (no) 2007-05-22
EA011773B1 (ru) 2009-06-30
KR20070045351A (ko) 2007-05-02
ZA200702364B (en) 2008-09-25
PE20060629A1 (es) 2006-08-11
EA200700492A1 (ru) 2007-08-31
AU2005276619B2 (en) 2009-04-30
IL180905A0 (en) 2007-07-04
MX2007002141A (es) 2007-04-27
AR050467A1 (es) 2006-10-25

Similar Documents

Publication Publication Date Title
EA200700492A1 (ru) Соли лерканидипина
DK4408840T3 (da) Benzimidazolcarboxylsyrer i deres egenskab af glp-1r-agonister
BRPI0514543A (pt) sais de metanossulfonato de abiraterona-3-ésteres e recuperação de sais de abiraterona-3-ésteres de solução em éter de terc-butila de metila
CY1118992T1 (el) Μεθοδοι παραγωγης κυκλοαλκυλκαρβοξαμιδο-πυριδινο βενζοϊκων οξεων
PE20141174A1 (es) Compuestos de pirrol como inhibidores de la bomba de protones
PE20230377A1 (es) Composicion de acido sulfurico y sus usos
BRPI0500585A (pt) Processo para a sìntese de ivabradina e sais de adição desta com um ácido farmaceuticamente aceitável
CY1108321T1 (el) Καινοφανη παραγωγα δικαρβοξυλικου οξεος
BRPI0905147A8 (pt) processo para síntese de ivabradina e seus sais de adição com um ácido farmaceuticamente aceitável
CY1109896T1 (el) Εξω- και διαστερεο- εκλεκτικες συνθεσεις αναλογων της ιμβακινης
BRPI0812625A2 (pt) processo para preparar um sal de cis-atracúrio
NI200900134A (es) Derivados de imidazol como inhibidores de proteína de huso de cinesina (eg-5).
BR112012021556A2 (pt) processo para a preparação de peptídeos prolila substituídos e peptidomiméticos similares
EA200000804A1 (ru) Мета-азациклические соединения аминобензойной кислоты и их производные, являющиеся ингибиторами интегрина
BR0210531A (pt) Derivados de ácido sulfÈnico
BRPI0414436A (pt) processo para a preparação de derivados de 2-oxo-1-pirrolidina e seus sais
NO20081207L (no) Isoquinolines as IGF-1R inhibitors
BRPI0116227B8 (pt) processo para a preparação de imidazotriazinonas substituídas por sulfonamida
BR0309120A (pt) Compostos com atividade antagonista de integrina alfa4
BRPI0516595A (pt) processo para fabricar um composto, e, composto
UY29343A1 (es) Pirazolopiridinas y sales de las mismas, una composición farmacéutica que comprende dichos compuestos, un método para prepararlos y su uso.
BR112012003616A8 (pt) Metilpirrolopirimidinacarboxamidas
AR051341A1 (es) Proceso para la preparacion de derivados de [1,4,5]-oxadiazepina
BRPI0607230A2 (pt) inibidores de protease hiv
ECSP088737A (es) Nuevos compuestos cristalinos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.